Numbers

Claude View

The Numbers

Best Agrolife trades at ₹17.8 per share (₹630 Cr market cap), or 0.78x book value – the cheapest in its agrochemical peer set. The stock is down 50% from its 52-week high of ₹35.8. The single metric most likely to rerate or derate this stock is ROCE: it has collapsed from 41% to 13% in two years, and the market is pricing in continued mediocrity. A recovery above 20% ROCE would force a rerating; another year below 15% confirms the discount is deserved.

Valuation Snapshot

The stock trades just 45% above its 52-week low of ₹12.3 and 50% below its 52-week high. A 1:10 stock split and 1:2 bonus issue (record date: January 16, 2026) increased share count significantly, which partly explains the low absolute price. At 0.78x book, the market assigns virtually no franchise value to the branded products business.

Revenue and Earnings Power

Revenue has plateaued near ₹1,800 Cr after the FY21-23 surge. The real story is earnings compression: EBITDA has halved from ₹314 Cr to ₹200 Cr, and PAT has collapsed from ₹192 Cr to ₹70 Cr. Interest costs doubled (₹39 Cr to ₹66 Cr) and depreciation nearly doubled (₹24 Cr to ₹43 Cr), compounding the margin squeeze.

Quarterly Performance

The business is violently seasonal. Q1 (Kharif sowing) and Q2 (monsoon peak) generate nearly all annual profit, while Q3 and Q4 are breakeven or loss-making. Q3 FY26 revenue was ₹203 Cr, down 26% YoY. 9M FY26 revenue stands at ₹1,101 Cr – annualized, that suggests FY26 revenue of ~₹1,500-1,600 Cr, a meaningful decline from FY25's ₹1,814 Cr.

EPS Trajectory

EPS peaked at ₹5.41 in FY23 and has declined 64% to ₹1.97 in FY25. At the current price of ₹17.8, the trailing P/E of 26x looks expensive for a business with declining earnings. For the P/E to appear cheap, the market needs to see a sharp earnings recovery – which requires both margin expansion and revenue stabilization.

Cash Generation – The Inflection Point

This is the most important chart in this report. After three years of cumulative cash burn totaling ₹294 Cr (FY22-24), free cash flow turned sharply positive at ₹208 Cr in FY25. The FCF yield of 33% against market cap is extraordinary – if sustainable. The turnaround was driven by inventory liquidation (577 days from 864) releasing trapped working capital. The critical question is whether this is a one-time release or a structural improvement.

Balance Sheet and Leverage

Total liabilities fell from ₹1,366 Cr to ₹1,191 Cr in FY25 – the first contraction in the data. Equity grew to ₹758 Cr from retained earnings. The debt-to-equity ratio improved from 0.90x (FY24) to 0.48x (FY25).

The deleveraging is real. Net debt/equity halved from 0.90x to 0.48x. However, interest expense of ₹66 Cr on EBITDA of ₹200 Cr means interest coverage is only 3.0x – adequate but not comfortable.

The Critical Chart: Interest Burden vs Earnings

Interest coverage has deteriorated from 16.8x to 3.0x in four years. Interest expense grew 13x (₹5 Cr to ₹66 Cr) while EBITDA grew only 2.4x. The company took on debt to finance the inventory build-up, and interest now consumes 33% of operating profit. One more weak year pushes coverage toward 2.0x, which would trigger lender discomfort.

Working Capital – The Core Problem

Inventory days improved from 864 to 577 but remain extreme – a well-run formulator like Dhanuka operates at 80-100 days. Debtor days have worsened from 53 (FY21) to 113 (FY25), indicating the company is extending more credit to maintain sales. CCC at 286 days is improving but still double the industry norm of 120-150 days.

Return on Capital – The Scorecard

ROCE at 13% is below any reasonable cost of capital estimate for a mid-cap Indian agrochemical company (14-16%). The business is currently destroying value for equity holders. The gap between the FY22 peak of 41% and today's 13% reflects both margin compression and a bloated capital base. For the stock to rerate, ROCE must recover above 20%.

Shareholding – Institutional Exit

FII holding has halved from 10.8% (Q1 FY24) to 5.5% (Q4 FY26) – a sustained institutional exit over 12 quarters. DII holding is minimal at 2.1%. The retail shareholder count nearly doubled from 38k to 68k in Q4 FY26, driven by the bonus/split making the stock accessible to smaller investors. Promoters marginally increased holding to 50.4%, a modest positive signal.

Peer Comparison

Best Agrolife clusters with Rallis in the low-ROCE, low-margin quadrant. Dhanuka and Sumitomo occupy the premium quadrant with 20%+ ROCE and 20% margins. The gap between Best Agrolife's 13% ROCE and Dhanuka's 28% ROCE is the entire investment thesis – if the branded transition succeeds, the company migrates up and to the right. If it does not, the current valuation discount is permanent.

What the Numbers Confirm, Contradict, and Demand

The numbers confirm two things: the balance sheet is healing (FCF turned positive, debt/equity halved from 0.90x to 0.48x), and the branded transition is progressing (66% branded mix, 30% patented share). The numbers contradict the bull narrative on one critical point: margins have not expanded despite the branded shift – EBITDA margins are 11% (FY25) vs 14% (FY22) when branded was only 54%. This suggests the branded premium is being offset by inventory losses, rising interest costs, and competitive pricing pressure.

Watch three things next quarter: whether FY26 revenue decline stabilizes or accelerates; whether inventory days break below 400; and whether interest coverage holds above 3.0x. The stock at 0.78x book is priced for mediocrity. Any evidence of margin recovery triggers a sharp rerating – but the burden of proof remains squarely on the company.